WuXi AppTec announced robust double-digit growth in revenue and profit for the first three quarters of 2025. The company also reported a 41.2% year-over-year increase in its backlog for continuing operations. Based on this strong performance, WuXi AppTec has further raised its full-year 2025 guidance, indicating continued positive momentum and market demand for its services.
This strong financial performance and upward revision of guidance signal robust demand for WuXi AppTec's CRDMO services, indicating market confidence in its business model and execution. The significant increase in backlog suggests sustained future revenue streams. This financial health is crucial for continued investment in R&D, expansion of capabilities, and maintaining its competitive edge in the global pharmaceutical services market.
Double-digit revenue and profit growth for Q1-Q3 2025.
Backlog for continuing operations up 41.2% YoY.
Full-year 2025 guidance has been further raised.
The financial results reflect WuXi AppTec's global operations and its performance across various markets where it provides pharmaceutical R&D and manufacturing services.
Full-year 2025 guidance has been further raised.
Indicates strong market demand and operational success.
Sign in to save notes on signals.
Sign In